Big Pharma is rethinking the clinical trials process, establishing tighter links between clinical R&D and discovery. The buzzword is experimental medicine--a catchall for the set of tools and clinical strategies used to determine whether hitting a drug target modulates a disease process in a therapeutically useful way. By so doing, companies hope to reign in clinical costs--the bulk of drug development expenses--by avoiding massive drilling into what prove to be dry drug development holes. To some, experimental medicine is also a process to create a bridge between discovery research and clinical R&D--a large task given that they hold different mindsets.
By Mark L. Ratner
Over the past decade, spurred by the availability of genomics data, chemistry-oriented Big Pharma has acquired the toolkits of molecular...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.